The number of circulating LDL particles is a strong indicator of future cardiovascular disease (CVD) events, even superior to the concentration of LDL cholesterol. Atherogenic (primarily LDL) particle number is typically determined either directly by the serum concentration of apolipoprotein B (apo B) or indirectly by nuclear magnetic resonance (NMR) spectroscopy of serum to obtain NMR-derived LDL particle number (LDL-P).
ticle number has been found to be a stronger predictor of CVD than LDL-C concentration (2 ) .
The focus of this special report is the comparison between the 2 main diagnostic tests for LDL particle number, namely concentration of apolipoprotein B (apo B) and nuclear magnetic resonance (NMR)-derived LDL particle number (LDL-P), in their association with CVD and related conditions as outcome measures.
apo B is the main protein component of LDL and, because each LDL particle has 1 molecule of apo B, it is considered to be a direct measure of LDL particle number (2 ) . The full-length form of apo B, called apo B-100, is found on VLDL, intermediate density lipoprotein (IDL), LDL, and lipoprotein(a) [Lp(a)], whereas a truncated form, called apo B-48, is found on chylomicrons and chylomicron remnants. Because of its relatively high abundance, apo B is readily measured in the clinical laboratory by several methods. The most common commercial assays are the immunoturbidimetric assay (ITA) and the immunonephelometric assay (INA). Typically, these methods measure both apo B-100 and apo B-48, but in fasting samples greater than 95% of apo B in plasma is apo B-100 and almost all of it is associated with LDL (6 ) . Therefore, the measurement of plasma apo B concentration is essentially an estimate of LDL-apo B concentration or LDL particle number (7 ) . Calibration of these assays is attained through the use of calibrators provided by the assay kit manufacturer, which may now have set points established by the CDC Lipid Standardization Program (LSP) using the WHO-IFCC reference material SP3-08 as secondary reference material and the designated comparison method (DCM). In many studies, apo B has been shown to be superior or at least equivalent to LDL-C for assessing patients for CVD risk (2 ) .
LDL particle number can also be estimated by NMR of plasma (8 ) , a proprietary method that has been available since 1997 as part of the NMR LipoProfile® from LipoScience, a specialty lipid reference laboratory. The terminal methyl groups on lipoproteinassociated lipids emit a characteristic NMR spectrum, which varies depending on the size of the lipoprotein particle, allowing NMR to estimate the different size LDL and other lipoprotein subfractions (9 ) . A specific spectral region captures the NMR signal emitted by the total number of terminal methyl group protons of phospholipids, cholesterol, cholesteryl esters, and triglycerides of the different lipoprotein particle subclasses (10 ) . A least squares deconvolution process is used to calculate the individual subclass signal amplitudes. The deconvolution algorithm was developed using a library of different lipoprotein size subclasses, obtained from a diverse donor population, containing isolated VLDL, LDL, and HDL. Total LDL-P is determined by summing the concentrations of the individual LDL subfractions, including IDL and Lp(a). Numerous studies have shown the superiority of LDL-P over LDL-C for both identifying patients at CVD risk and in monitoring patients on lipidlowering therapy (2 ) .
Ion mobility analysis has been proposed as another method to measure LDL particle number directly (11 ) , although the accuracy of the method has been disputed (12 ) . This assay currently is available only at Quest Diagnostics Nichols Institute. Ion mobility analysis has been reported for only one clinical study (13 ) and has not been compared to other LDL-P assays.
Non-HDL-C has also been shown in several studies to be a predictor of CVD events (5, 14 ) and serves as a secondary treatment goal by the NCEP for those patients with hypertriglyceridemia who have met LDL-C treatment goals. Non-HDL-C is readily calculated from standard lipid panels as the difference between total cholesterol and HDL-C and, similar to apo B, encompasses all putative atherogenic lipoproteins. Although non-HDL-C reflects total atherogenic particle number better than LDL-C, unlike apo B, non-HDL-C does not accurately reflect atherogenic particle number and may leave residual CVD risk after treatment goals are met, due to the variability of the composition of the constituent lipoproteins.
In this study, we reviewed the literature on apo B and LDL-P and examined 25 clinical studies that included both parameters to compare their utility as biomarkers for CVD risk, as well as other related conditions and parameters, such as carotid intima media thickening (CIMT), diabetes and metabolic syndrome (MetSyn).
Methods
A PubMed survey of the medical literature, using the key terms apo B, LDL-P, and the name Otvos, was performed to find clinical trials of the association of both apo B and LDL-P with specific outcomes, such as CVD, the presence of carotid atherosclerosis, or metabolic diseases or conditions, including diabetes mellitus and MetSyn. A total of 26 publications was found through June 2012. One publication with an outcome of newborn body weight (15 ) was excluded from our analysis. The relevant data for each clinical study is summarized in Table 1 . Each study was identified with an order number, study acronym, and year of publication, e.g., 1 Veterans Affairs High-Density Lipoprotein Intervention Trial (VA-HIT) 2006. An assessment was made for each clinical study or relevant portion thereof whether apo B or LDL-P was statistically related to the outcome ( Table 2) . The study or subpart was then assigned to 1 of 4 outcome categories: 1. apo B statistically significant, LDL-P not significant; 2. LDL-P statistically significant, apo B not significant; 3. both statistically significant; or 4. neither statistically significant. 
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Results
REVIEW OF SURVEYED PUBLICATIONS
Comprehensive summaries of the 25 surveyed clinical studies are presented in the Data Supplement that accompanies the online version of this report at http:// www.clinchem.org/content/vol59/issue5. The associations of apo B and LDL-P to clinical outcomes are shown in Table 1 . Depending on the study design and statistical analyses, associations are indicated by odds Table 1 footnote.
Fig. 1. Comparison of association of apo B and LDL-P to various clinical outcomes based on OR, RR, or HR.
a For study 4 HPS 2012, P values were derived by the authors from 1 2 values given in the publication. b Revasc., revascularization; OCE, other cardiac event; Isch., ischemic; LRC, lipid rich core; M1, model 1; M2, model 2; adj., adjusted; M, male; F, female; B, both. Other nonstandard abbreviations not defined in the text and information about study reference citations are provided in Table 1 . c Study 12 ARIC 2011 did not provide 95% CIs around the OR.
ratio (OR), hazard ratio (HR), relative risk (RR)
, regression analysis, or comparison of means. ORs, HRs, and RRs are also illustrated as a forest plot in Figure 1 , providing the risk estimate Ϯ95% CI for a 1 mean (SD) increment in the biomarker concentration. Intervals which fall below 1.0 are considered statistically not significant. The comparisons of apo B and LDL-P are shown in Table 2 , based on the 4 outcome categories described in Methods, using data shown in Table 1 and Figure 1 . A brief summary of findings for various outcomes follows.
Prediction of CVD or events. In 15 of 19 comparisons, apo B and LDL-P both were associated (n ϭ 12) or neither was associated (n ϭ 3) with study outcomes, giving a high concordance between the 2 biomarkers (78.9%), particularly with regard to prediction of future CVD events (16 -22 ) . On the basis of risk ratios, LDL-P was more strongly associated with events in the Because of the lack of data for non-HDL-C, a meaningful 4-way comparison with apo B and LDL-P was possible for only the 6 studies in this prediction category (see online Supplemental Table 1 ). In this limited data set, apo B, LDL-P, and non-HDL-C were comparable in the number of comparisons which were significant (13 to 15 of 19 total comparisons), whereas LDL-C was significant in only 9 comparisons.
Presence of carotid atherosclerosis. Both apo B and LDL-P were strongly predictive of carotid atherosclerosis (23) (24) (25) (26) (27) . For most outcomes LDL-P was a stronger predictor than apo B. Both apo B and LDL-P agreed in 17 of 24 outcomes, for a concurrence rate of 70.8%.
Prediction of MetSyn. In 8 of 9 clinical outcomes (88%), apo B and LDL-C were equivalently associated with the presence of MetSyn or with the effect of statin therapy on patients with MetSyn (28 -30 ).
Association with diabetes mellitus or diabetic complications. In general, both apo B and LDL-P were equally associated with diabetic nephropathy and distribution by sex and glycemic control in individuals with type 1 diabetes (31) (32) (33) (34) . In addition, the strengths of the associations were similar. Similar reductions of both apo B and LDL-P were observed as a result of treatment of individuals with type 2 diabetes with colesevelam. Overall, 14 of 16 outcomes were in agreement between apo B and LDL-P (87.5%).
Association with plasma lipids and lipoproteins.
A consistent role of apo B or LDL-P in this grouping is not evident because of the number of outcomes in which both parameters were not statistically significant; however, in instances in which both were significant, both were generally affected to the same extent (35) (36) (37) (38) (39) .
Prediction of miscellaneous associations. In the 1 small study reported for venous thromboembolic disease (VTE) [24 Venous Thromboembolic Disease Study (VTES) 2005], LDL-P was superior to apo B in predicting VTE in men; LDL-P alone was statistically significant for all outcomes (n ϭ 4) ( 40 -41 ) . Both apo B and LDL-P predicted incident hypertension (HTN) in initially healthy women, but the ORs were larger for LDL-P than for apo B.
ASSESSMENT OF OVERALL CONCORDANCE BETWEEN apo B AND LDL-P ACROSS STUDIES
The comparisons were grouped into 1 of 4 distinct outcome categories as described in Methods. For the 25 studies reported here, both apo B and LDL-P were significant for at least 1 outcome in 21 (84.0%) of the 25 studies. Neither was significant for any outcomes in only 1study. In 2 studies, LDL-P was significant for at least 1 outcome whereas apo B was not, and in 1 study apo B was significant for at least 1 outcome whereas LDL-P was not. In the 25 studies, there were a total of 85 outcome measures compared. Table 2 shows that, of a total of 85 observed comparisons of various types, 50 fell into the "both statistically significant" category (58.8%), 13 fell into the "LDL-P statistically significant, apo B not significant" category (15.3%), and 5 fell into the "apo B statistically significant, LDL-P not significant" category (5.9%). These data indicate that both apo B and LDL-P were generally in agreement in their association with diverse clinical outcomes (58.8%), but with a substantial amount of discordance (21.2%) in which one biomarker was statistically significant whereas the other was not. The "neither statistically significant" category (20.0%) is considered noninformative because it does not allow a comparison of one biomarker to the other. Although several comparisons showed equivalent strength of association with the outcome measures for apo B and LDL-P, in some cases one or the other biomarker appeared to be more strongly associated with the outcome variable. In these cases, LDL-P showed a significant association with a clinical outcome more often than apo B alone, and the level of statistical significance, as indicated by the P value, and the strength of association, as indicated by the OR, RR, and HR, was more often higher for LDL-P than it was for apo B (Table 1, Figure 1) .
Discussion
At present, LDL-C is used as the primary lipoprotein indicator of cardiovascular risk in the US and serves as the primary treatment goal in the NCEP-ATP III guidelines. As new clinical studies emerge, the relative utility of biomarkers for assessment of CVD should be reevaluated and treatment guidelines revised accordingly. This occurred in Canada, where apo B measurements were incorporated into the clinical guidelines for the assessment of CVD in 2003 (42 ) . Similar recommendations have recently been made in the US (5 ) .
As reviewed recently, LDL particle number, as either apo B or LDL-P, has been shown to be a better predictor of future CVD events than LDL-C and a better monitor of therapy in many (2 ), but not all, studies (18, 21, 43 ) . Although the clinical utility of the measurement of LDL particle number is currently debated, the recent report from an expert panel of lipid specialists presents a reasonable use of these biomarkers for diagnostic and monitoring purposes in selected groups of patients (5 ) . Given that both apo B and LDL-P measure the same atherogenic indicators, primarily LDL particle number, their association with various disease states or conditions would be expected to be strongly related. To determine their relative utility, we chose to review all publications that allow direct comparison of the association of apo B and LDL-P to clinical outcomes. Our review of 25 relevant publications shows that neither was consistently superior to the other (Table 2). Less clear is the lack of equivalency that is observed in some studies, which, as discussed below, may be due to differences in the analytical methods used to measure these biomarkers.
As observed in our limited comparison of 4 biomarkers (see online Supplemental Table 1 ), both non-HDL-C and apo B are superior to LDL-C in predicting CVD risk. Conventional wisdom is that non-HDL-C is better than LDL-C because it includes the cholesterol in VLDL. However, it has been clearly shown that the amount of cholesterol in VLDL particles cannot explain the increased RR seen with non-HDL-C versus LDL-C (44 ). The better explanation is that non-HDL-C more accurately reflects the number of LDL particles (44 ) . In a metaanalysis of LDL-C, non-HDL-C, and apo B as risk factors for CVD, Sniderman et al. demonstrated the superiority of apo B over non-HDL-C and LDL-C, with RRs in the order apo B Ͼ non-HDL-C Ͼ LDL-C (45 ) . These data suggest that treating to goal with non-HDL-C leaves residual risk.
COMPARISON OF apo B ITA/INA AND LDL-P METHODS
The reliable application of risk cutpoints and treatment goals, which are based on data derived from epidemiologic trials, requires precise and accurate analytical measurements to be medically useful (Table 3) . Relatively small errors in measurement can lead to the misclassification of individuals with regard to risk, with potentially serious consequences (4 ) . The accuracy of a method is established by standardization, a process involving a reference system of primary and secondary reference measurement procedures and reference materials, which assures that reported results for an analyte will agree with other laboratories over time, independent of methodology (46 ) . Bias, the measure of inaccuracy, is the difference of a measured value from the true value of an analyte. Bias among laboratories in the measurement of apo B would be minimized if they all used standardized methods, but for most of the studies reported here, it is not possible to determine whether standardized assays were used or used in the format under which they were standardized (see online Supplemental Table 2 ). None of the 25 publications reviewed provided a measure of bias to a reference method. Precision is a measure of the reproducibility of measurement and is expressed as % CV. An imprecise method, even though on average free of bias, will still result in excessive error on individual measurements. Together, accuracy and precision define the total error associated with a measurement process. Performance goals for accuracy and precision for an analyte are set so that the requisite medical usefulness of a biomarker is attained. At this time, no performance goals have been established by the NCEP or any other expert panel for either apo B or LDL-P (46, 47 ) . However, a 6.0% maximum bias, based on biological variation and analytical imprecision, has been suggested for apo B, which is similar to the one for LDL-C (6.8%) (48 ) . No such information is available for LDL-P. A standardization program for apo B is provided by the Northwest Lipid Metabolism and Diabetes Research Laboratories (NWLMDRL) in Seattle, WA, which determines precision and bias relative to an in-house method, accepted as a DCM for apo B by the CDC LSP (47 ) . Thus, apo B is standardized using the same CDC LSP which is used for the standardization of cholesterol, LDL-C, and HDL-C. The strategy of the LSP is to work directly with manufacturers to standardize their commercial assays, which are then used by clinical laboratories. Although there is no formal standardization program for LDL-P, it could conceivably conform to the apo B LSP, by adding the VLDL particle number to the LDL-P and converting nanomoles per liter (nmol/L) to mass units (mg/dL) based on the molecular weight of apo B (550 000 Da) (49 ) . This conversion recognizes that both total plasma apo B and LDL-P measurements presumably include IDL and Lp(a), in addition to LDL.
The methods for only 4 studies listed in online Supplemental Table 2 were stated to be standardized for apo B, and that was by verification of calibration to the apo B assay kit manufacturer, Incstar, which had taken part in the WHO-IFCC standardization program using SP3-07 as reference material (50, 51 ) . Presumably, a single laboratory performed the apo B measurements for these studies. Three other laboratories were described as standardized through the LSP for lipids, but it is not clear that they were also standardized for apo B (see online Supplemental Table 2 ). Standardization was not claimed for any of the remaining 17 methods. As noted by several authors, a major concern about the use of apo B for assessment and treatment of CVD is the lack of rigorous standardization among methods and laboratories (49, 52 ) . Interestingly, this concern has not been shared for LDL-P, which is not standardized to any reference system, because it is measured in only one laboratory, thereby eliminating the problems of among-method and among-laboratory variability. In fact, standardization is not a prerequisite for the establishment of an association of a biomarker with a clinical outcome within any single laboratory and study, but it is critical for comparison between laboratories and studies or if data from several laboratories will be pooled for the establishment of disease risk assessments or treatment cutpoints.
A major advantage of the NMR method vs apo B is the determination not only of LDL-P but also LDL subclasses and other major lipoprotein classes; thus NMR provides considerably more information with the analysis than does the measurement of apo B. Although additional information may contribute to the value of an assay, only that information which has been shown to provide proven clinical significance should be reported to the patient. Also, the NMR measurement of LDL-P appears to be generally more precise than that of apo B. For the few laboratories that reported % CV for the measurement of apo B, it is assumed to be a measure of between-run precision, with CVs ranging from 5% to 11%, whereas the same measure for LDL-P was from 2% to 4% (8 ) . This disparity in precision may give LDL-P an advantage over apo B in discerning small differences between groups in a clinical study. According to the College of American Pathologist's proficiency testing reports [2011 Accuracy-Based Lipid Surveys, ABL-A and ABL-B (http://www.cap.org/apps/ cap.portal)] for apo B, the within-method, betweenlaboratory precision averaged about 5.96% for all the methods tested and the overall precision (between method/between laboratory) precision averaged about 6.75% for all methods in their program. In contrast, LDL-P has no between-laboratory precision value because it is measured in only one laboratory. In addition, the measurement of LDL-P in a single laboratory would also be expected to benefit from the long-term stability of measurement, although the deconvolution algorithm used by LipoScience has evolved over time (53 ) . In contrast, the stability of apo B measurements requires the assay kit providers to reassess the calibrator accuracy with each change in the lots of antisera and calibrators. The lack of between-laboratory variability and extended long-term stability would allow pooling of LDL-P data collected in different clinical studies over long periods of time with less variability than for apo B data, which may be impacted by the assay antibody and method as well as laboratory and assay bias issues. Several other factors may also impact the use of apo B and LDL-P measurements (Table 3) .
Samples. For both methods, serum or plasma from either fed or fasted individuals may be used. Samples have been reported to be stable for at least 10 years for NMR analysis when frozen at Ϫ70 o C, allowing the analysis of reserved study samples (8 ) , whereas apo B changes that occur upon freezing and storage appear to be method dependent (54 ) . The NMR-based LDL-P assay uses 200 L of sample and the immunoassay of apo B generally requires only about 2 to15 L of sample (depending on the vendor).
Test availability. Increasing recognition of the superiority of measures of particle number over LDL-C will likely drive increased demand for apo B and LDL-P measurements. The number of lipid panels performed annually in the US to obtain LDL-C is estimated to be 216 000 000 (55 ) . Considering the implications of a shift to particle measurement, it must be recognized that the apo B measurement is inherently scalable, with many vendors providing assays that can be performed on almost every chemistry analyzer in any clinical laboratory and physician office (Table 3) . Although the LDL-P test is performed only by the LipoScience reference laboratory, LipoScience has recently received US Food and Drug Administration clearance for distribution of its NMR analyzers for lipoprotein testing to other clinical laboratories. Nevertheless, the capital expense and logistical complications initially may still limit availability of the LDL-P assay.
Expense. Based on the Medicare fee schedule, the incremental cost of adding an apo B or LDL-P test to a lipid panel is about $17 or $30 -$40, respectively, depending on the payer. There is some concern as to the cost benefit of the added testing given the additional expense (52 ) . However, according to at least one US Expert Panel the incremental expense is warranted in certain patients (5 ) . The therapeutic value relative to the incremental cost of each of the measurements is currently under aggressive debate (5, 56 ) .
SUGGESTED EXPERIMENT TO FURTHER COMPARE apo B TO LDL-P
A limitation of our study is that none of the studies reviewed were specifically designed to compare results and clinical utility of apo B vs LDL-P. Further work is recommended to compare these methods on a variety of sample types and determine their utility as predictive biomarkers in various diseases and conditions. An example of an appropriate study was recently described by Miller, et al. (3 ) . Briefly, samples were collected from healthy individuals and from individuals with a variety of dyslipidemic and cardiovascular diseases. The samples were analyzed with a panel of HDL-C and LDL-C clinical assays, as well as by the appropriate reference measurement procedures. Trueness and total error relative to the RMP were determined. A similar experiment should be conducted using a variety of standardized apo B assays and the LipoScience LDL-P assay and comparing with the CDC LSP DCM for apo B. To make a suitable comparison to plasma apo B, NMR VLDL-P values would need to be added to the LDL-P (nmol/L), which would then be converted to apo B equivalents (mg/dL) by multiplication by the factor 0.055 (49 ) . As has been previously described when comparing the clinical utility of LDL-P vs LDL-C as a biomarker (57 ) , the discordant cases between apo B vs LDL-P will likely be most revealing in terms of the relative merits of the 2 tests.
When compared for all the clinical outcomes in the 25 publications reviewed here, associations of apo B and LDL-P were generally equivalent, although when discordance between associations with outcome measures occurred, LDL-P appeared more often to be superior to apo B, based on statistical strength. The finding that the 2 biomarkers show similar CVD risk prediction is expected given that both methods measure, in addition to LDL-P, the particle numbers of IDL and Lp(a). Total plasma apo B may additionally in-clude VLDL and chylomicron remnants, which are typically present in small quantities in fasting samples. Although a standardization program for apo B exists, it appears from an inspection of the published studies to be underutilized, particularly for measurements made in older clinical studies, thereby confounding the use of pooled data from multiple trials to set disease assessment and treatment cut-points.
RECOMMENDATIONS
Based on the preceding observations, we make the following recommendations:
1. The measurement of particle number, either as concentration of apo B or LDL-P should be incorporated into the guidelines for the assessment of CVD risk. 2. Manufacturers of analytical systems for measurement of apo B concentration or particle number should produce well-characterized, robust assays with disclosure of analytical properties, such as antibody specificity, and information regarding standardization. 3. All manufacturers should standardize their assays according to WHO-IFCC reference materials by the currently available standardization program at the NWLMDRL using the apo B DCM. 4. Researchers and laboratories using these assays in clinical studies should calibrate or verify the accuracy through the use of frozen serum samples from NWLMDRL. 5. Performance goals (precision, bias, total error) for LDL-P assays should be determined by expert consensus, as was done for other lipid/lipoprotein biomarkers. 6. Additional studies should be performed to determine the optimum specificities for apo B antibodies (e.g. apo B-100, apo B-48, apo ͓a͔), and to the various apo B-carrying particles, to best characterize CVD risk and monitor therapy. 7. Further studies should be performed to compare apo B to LDL-P using a variety of representative specimens to better understand the inherent differences and contributors to discordance, as well as relative advantages and disadvantages of the 2 assays.
Conclusions
In the majority of studies, both apo B and LDL-P were comparable in association with clinical outcomes. Where discordant, the differences may be due to inherent methodological differences between the 2 technologies as well as the large number of methodologies employed to measure apo B and the consistency of the NMR method, which was performed using a single method in a single laboratory for all the studies. The 2 markers appear to be nearly equivalent in their ability to assess risk for CVD, and as previously published by the Lipoprotein and Vascular Diseases Division Working Group on Best Practices, both measures have consistently been shown to be stronger risk factors than LDL-C (2 ). We continue to support the adoption of apo B and/or LDL-P as indicators of atherogenic particle numbers into cardiovascular risk screening and treatment guidelines. Currently, in the opinion of this Working Group on Best Practices, apo B appears to be the preferred biomarker for guideline adoption because of its widespread availability, scalability, standardization, and relatively low cost. As LDL-P is expected to become more readily available in the near future, with a possible lowering of cost and potentially superior performance in direct comparison with apo B, it may become the preferred test as a cardiovascular biomarker. Although this study primarily was aimed at comparing apo B and LDL-P, results of our limited evaluation of non-HDL-C and current literature (44, 45 ) suggest that the high performance of non-HDL-C likely is related to being an indirect way of estimating apo B.
